BAIYUNSHAN PH announced that its holding subsidiary Tianxin Pharmaceutical's injectable ampicillin sodium (1.0g, 0.5g) has passed the consistency evaluation for quality and efficacy of generic drugs. In 2024, the sales volume of this Pharmaceutical in the domestic market is 692.01 million yuan, with Tianxin Pharmaceutical's sales revenue at 1.1507 million yuan. As of the announcement date, Tianxin Pharmaceutical has invested approximately 1.8284 million yuan in R&D expenses for this project.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
白云山:子公司药品通过仿制药一致性评价
BAIYUNSHAN PH: Subsidiary Pharmaceutical passed the consistency evaluation for generic drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 385
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report